16:35 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million on July 16 in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures,...
17:45 , Jul 18, 2018 |  BioCentury  |  Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday, joined...
16:45 , Jul 16, 2018 |  BC Extra  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Nohla adds $11M to series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised an additional $11 million on June 11 in the second close of a series B financing, bringing the round’s total to $56 million. New investors...
18:36 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million on June 19 in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital,...
22:01 , Jun 19, 2018 |  BC Extra  |  Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital, Bessemer Venture Partners,...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...